KM602 / Sihuan Pharmaceutical - LARVOL DELTA

Sihuan Pharmaceutical (00460): Recombinant Human CD80 Mutant-Fc Fusion Protein Injection and XZP-6877 Tablets, a drug developed by Xuanzhu Biotech, were approved for clinical trials [Google translation] (Zhitong Finance) - "Zhitong Finance APP News, Sihuan Pharmaceutical (00460) issued an announcement that the drug recombinant human CD80 mutant-Fc fusion protein injection (product code: XZP-KM602) developed by Xuanzhu Biotechnology Co., Ltd., a non-wholly owned subsidiary of the group, Both the selective DNA-dependent protein kinase (DNA-PK) inhibitor (product code: XZP-6877 tablets) have been approved by the State Drug Administration to carry out clinical trials for the treatment of advanced solid tumors."

New trial • Oncology • Solid Tumor